Introduction
Folate supplementation to the diet protects against cancer development and other diseases, while folates also protect against toxicity of antifolate-based treatments. For example, leucovorin is commonly used to reduce antifolate toxicity in leukemia and some solid tumors [ 1 , 2 ] , while folic acid is added to treatment with the antifolate pemetrexed (PMX) with cisplatin to reduce toxicity [ 3 ] . Interestingly, folic acid not only increased the efficacy of this combination but also that of cisplatin as a single drug.
In contrast to these aspects, we also demonstrated that folates induce the efflux of the anthracycline daunorubicin (DNR) via multidrug resistance protein 1 (MRP1)/ABCC1 in vitro [ 4 ] . This membrane-bound ABC transporter mediates drug resistance by effluxing a wide variety of structurally unrelated drugs [ 5 -7 ] and belongs to the MRP family [ 5 , 7 ] . Natural folates as well as antifolates, such as methotrexate (MTX) and PMX, are good MRP1 -3 substrates [ 8 -11 ] . MTX is used in the treatment of several types of cancer and inflammatory diseases [ 1 , Depending on the source, folates will enter the folate cycle directly (food as 5-methyl tetrahydrofolate) or indirectly (supplements, folic acid). Folic acid will be reduced by DHFR (dihydrofolate reductase) to dihydrofolate and tetrahydrofolate. An increase of 5-methyl-tetrahydrofolate will reduce homocysteine levels because the methyl group is used to convert homocysteine to methionine (catalyzed by MS with vitamin B12 as co-factor), which after conversion to S-adenosylmethionine will serve as a methyldonor for methylation reaction catalyzed by DNA methyltransferase (DNMT). Abbreviations: TS, thymidylate synthase; FPGS, folylpolyglutamate synthetase; MTHFR, methylene tetrahydrofolate reductase; MS, methionine synthase. 
Materials and methods

Materials
RPMI-1640 medium (containing 2.3 μ M folic acid), folate-free RPMI-1640 medium, normal fetal calf serum (FCS) and dialyzed FCS were obtained from GIBCO (Grand Island, NY, USA). Drugs and chemicals were of standard commercially available quality.
Cell lines and drug sensitivity
The human ovarian carcinoma cell line 2008, and its stable MRP1 transfectant 2008/MRP1 were kindly provided by Prof. Dr. P. Borst (The Netherlands Cancer Institute, Amsterdam, The Netherlands) [ 8 ] and cultured in standard (with folic acid) RPMI-1640 medium, supplemented with 10% FCS, 2 mM glutamine and 100 μ g/mL penicillin/ streptomycin. For folate deprivation, cells were cultured for 5 days in special folic acid-free RPMI-1640 medium supplemented with 10% dialyzed FCS, 2 mM glutamine and 100 μ g/mL penicillin/streptomycin. Aft er 3 days of culture in folate-free medium, sensitivity to the drugs of interest was determined using the sulforhodamine B (SRB) assay as previously described [ 15 ] .
Western blotting
Western blotting for MRP1 was performed as previously described [ 13 ] .
Homocysteine assay
Shortly, cell pellets (2 -5 million cells) were suspended in 200 μ L water, sonicated, followed by addition of 25 μ L cysteamine as internal standard (25 μ M). To release and reduce protein-bound thiols, 15 μ L 10% tri-n-butylphosphine in dimethylformamide was added for 30 min at 4 ° C, centrifuged and deproteinized with 150 μ L 10% TCA (with EDTA), and centrifuged. The supernatant (50 μ L) was mixed with 20 μ L sodium hydroxide, 150 μ L borate buff er containing EDTA and 50 μ L SBD-F solution (1 mg/mL) and incubated for 60 min at 60 ° C, followed by addition of 5 μ L concentrated H 3 PO 4 to acidify the mixture for reversed phase high-performance liquid chromatography analysis on a 5-μ m Supelco LC-18-DB C 18 column (Phenomenex, Utrecht, the Netherlands; 150 mm × 4.6 mm) using an isocratic elution with a 0.1 M phosphate buff er containing 5.66% acetonitrile at 1 mL/min, with fl uorescence detection at 385 nm excitation and 515 emission wavelengths.
Glutathione assay
For the glutathione assay, 2 -5 million cells were used, which were lysed in 500 μ L phosphate-EDTA buff er. GSH was measured in this lysate with a commercial kit which is based on the reaction of the sulfh ydryl group of GSH with DTNB (5,5 ′ -dithio-bis -2-nitrobenzoic acid, Ellman ' s reagent), which produces a yellow colored 5-thio-2-nitrobenzoic acid (TNB). The mixed disulfi de, GSTNB (between GSH and TNB) that is concomitantly produced, is reduced by glutathione reductase to recycle the GSH and produce more TNB. The rate of TNB production is directly proportional to this recycling reaction, which in turn is directly proportional to the concentration of GSH in the sample. Measurement of the absorbance of TNB at 412 nm provides an accurate estimation of GSH in the sample. GSH is easily oxidized to the disulfi de dimer GSSG.
Results
The role of MRP1 expression on folate pools and drug sensitivity 
Effect of folate depletion on homocysteine and glutathione pools
As an indicator for intracellular folate pools, we measured intracellular homocysteine levels in these cells ( Table 1 ) 
Discussion
Since the 1970s folate supplementation is often routinely embedded in chemotherapy-based cancer treatment protocols to reduce drug toxicity [ 1 ] . More recently, it has also been exploited as a strategy to increase antitumor activity [ 3 ] . In addition, cancer patients increasingly take folate supplements as part of a healthy diet [ 17 ] . In the present study, we report, however, that high folate exposure in vitro provokes the ABC transporter MRP1, which mediates cellular drug resistance, not only for antifolates such as MTX but also doxorubicin and DNR. We describe that a decrease in (cellular) folate levels apparently reduces MRP1-mediated cellular efflux of its substrates and increases its sensitivity. Of interest is that levels of folates in human plasma, normal human tissues and solid tumors are normally low (between 5 and 20 nM) and are of the same order of magnitude as those in our folate-deprived cells in vitro [ 18 -20 ] . Nutritional intake of folates via food and dietary supplements largely controls folate homeostasis [ 21 ] . Folate supplementation can result in significantly higher plasma levels and influence cellular processes that are dependent on folates and alter sensitivity to antifolates. However, the ' folate-rich ' concentrations used in our study (i.e., normal culture medium, HF) are still much higher than normally found in human plasma. Yet, our results represent a proofof-principle that can possibly be translated to the physiological situation after supplementation.
Although we show here that high folate levels result in MRP1-associated drug resistance in vitro ( Figure 4 ) , it remains to be elucidated whether this can also affect multidrug resistance in patients. Besides, low folate conditions may be responsible for other effects, such as severe toxicity in normal cells. Especially for the use of antifolates, such as MTX, this is an important issue. In our experiments, we observed an extreme reduction of IC 50 for MTX as a function of folate deprivation, compared with the use of other drugs. This phenomenon is most likely not ascribed to MRP1 function alone. Previous publications showed that cellular folate status has a large influence on sensitivity to polyglutamylation-dependent antifolates in general [ 22 , 23 ] .
Folates have a striking similarity with the cellular compound GSH. GSH is a crucial factor in the MRP1-mediated transport of the cation DNR. GSH was described as (i) a co-substrate in transport of positively charged drugs [ 24 ] and (ii) to form a conjugate with positively charged drugs [ 14 ] ( Figure 5 ). Interestingly, folates and GSH both contain a glutamate residue that might play a role in binding to a reactive site in MRP1. Accordingly, folates might induce MRP1 activity by binding to this site, as proposed for GSH by Borst et al. [ 25 ] . By contrast, in our present study we show that folates also enhance MRP1-mediated transport. Changes in cellular levels of homocysteine as a result of lowered folate status might, for example, affect catalytic activity of several proteins [ 26 ] , but whether this influences MRP1 is not known. Following long-term folate deprivation ( > 3 months), however, MRP1 protein expression and efflux function can be markedly lost [ 27 ] .
In conclusion, folate supplementation can have several effects: reduction of toxicity, increase of antitumor activity, but also (as we demonstrate here) induction of MRP1-associated cellular drug resistance. An additional intriguing question is whether the effect of folates on MRP1 activity can be exploited to alter the transport of non-toxic physiological MRP1 substrates, such as leukotrienes, GSH and natural folates. This makes continued studies on the relationship between folates and MRP1 highly worthwhile and relevant. Folate intake and folate levels should be monitored more closely in cancer patients during chemotherapy than is currently the case. 
